Related Experiment Video
Updated: Jun 11, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Updating progress in sarcoma therapy with mTOR inhibitors.
1Department of Medical Oncology, Centre Léon Bérard, Lyon, France. BLAY@lyon.fnclcc.fr
Summary
The mammalian target of rapamycin (mTOR) pathway is a key target for treating difficult sarcomas. Inhibitors of this pathway show promise for improving outcomes in patients with poor-prognosis sarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Sarcomas are a heterogeneous group of challenging-to-treat connective tissue neoplasms.
- The mammalian target of rapamycin (mTOR) pathway is recognized as a significant therapeutic target in various sarcoma types.
Purpose of the Study:
- To review the role of the mTOR pathway in sarcoma development and progression.
- To update clinical data on available mTOR inhibitors for sarcoma treatment.
Main Methods:
- Literature search using PubMed and EMBASE databases.
- Selection of reference sources based on specific subtopics.
Main Results:
- The mTOR pathway regulates cell growth and proliferation and is often hyperactivated in human tumors.
- Dysregulation of the phosphatidylinositol-3' kinase (PI3K)-Akt signaling pathway is linked to diverse sarcoma subtypes.
- mTOR inhibitors (rapamycin, sirolimus, temsirolimus, everolimus, ridaforolimus) are being investigated for sarcoma treatment with variable success.
- The PI3K-Akt-mTOR pathway's involvement in resistance to antineoplastic therapies suggests mTOR inhibitors could re-sensitize resistant tumors.
Conclusions:
- The PI3K-Akt-mTOR pathway presents a promising therapeutic target for numerous solid malignancies.
- Blocking the PI3K-Akt-mTOR pathway offers a potential strategy to enhance outcomes for patients with poor-prognosis sarcoma.
More Related Videos
07:31A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...